Goldenwell Biotech (GWLL) Debt to Equity (2023 - 2025)

Goldenwell Biotech has reported Debt to Equity for 3 years, with the latest figure at -$1.17 in Q1 2025.

• For the quarter ending Q1 2025, Debt to Equity changed N/A year-over-year to -$1.17; the trailing twelve-month figure through Mar 2025 stood at -$1.17 (changed N/A YoY), and the FY2024 full-year result was -$2.02, down 326.79% from the prior year.
• Debt to Equity for Q1 2025 stood at -$1.17, up from -$2.02 in the prior quarter.
• The five-year high for Debt to Equity was $0.89 in Q4 2023, with the low at -$2.02 in Q4 2024.
• Historically, Debt to Equity has averaged -$0.77 across 3 years, with a median of -$1.17 in 2025.
• The largest YoY upside for Debt to Equity was 326.79% in 2024 against a maximum downside of 326.79% in 2024.
• Goldenwell Biotech's Debt to Equity stood at $0.89 in 2023, then slumped by 326.79% to -$2.02 in 2024, then surged by 42.12% to -$1.17 in 2025.
• The last three Debt to Equity figures came in at -$1.17 (Q1 2025), -$2.02 (Q4 2024), and $0.89 (Q4 2023), per Business Quant data.